Efficacy of Systane Balance to Stabilize the Tear Film in Dry Eye Subjects
NCT ID: NCT01086774
Last Updated: 2012-02-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
10 participants
INTERVENTIONAL
2010-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Outcomes Following Treatment With SYSTANE® BALANCE
NCT02776670
Evaluation of the Repeated Usage of Systane Ultra Eyedrop
NCT01051804
Evaluation of SYSTANE Ultra Lubricant Eye Drops
NCT00702377
SYSTANE® BALANCE Symptoms (OSDI) & Inflammatory Biomarkers
NCT01733732
The Effect of Systane Ultra Lubricant Eye Drops (FID 112903) on Visual Performance
NCT00673764
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Systane Ultra
Systane Ultra Lubricant Eye Drops
Systane Ultra Lubricant Eye Drops
Single drop in both eyes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Systane Ultra Lubricant Eye Drops
Single drop in both eyes
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subjects must have Tear Break Up Time (TBUT) \< 5 seconds
3. Subjects must have a maximum blink interval (MBI) \< 10 seconds
4. Subjects must be willing to comply with all study requirements.
5. Subjects must understand, sign and be given a copy of the written Informed Consent form.
2. Subjects who are pregnant, lactating or planning to be pregnant during the course of the study
3. Subjects with known sensitivity to planned study concomitant medications
4. Subjects participating in any other ophthalmic drug or device clinical trial within 30 days of this clinical investigation.
5. Use of ocular drugs, other than study medications, during the study and within 14 days prior to study entry or any other ocular medication
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alcon Research
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SMA-09-39
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.